Last updated: June 27, 2026
AstraZeneca Pharmaceuticals LP v. Agila Specialties, Inc (1:15-cv-06039) – Litigation Summary, Patent Issues, and Generic Risk Analysis
AstraZeneca Pharmaceuticals LP sued Agila Specialties, Inc. in 2015 in the District of New Jersey (case number 1:15-cv-06039). The dispute is a Hatch-Waxman patent litigation matter tied to AstraZeneca’s branded product(s) and Agila’s proposed generic(s), with typical stakes centered on Orange Book-listed patents, claim construction, and whether Agila could avoid infringement via noninfringement and/or invalidity arguments. The procedural posture, claims asserted, and the settlement or disposition outcome are not fully identifiable from the case identifier alone.
What happened in AstraZeneca Pharmaceuticals LP v. Agila Specialties, Inc 1:15-cv-06039?
Core event. AstraZeneca Pharmaceuticals LP filed a federal patent infringement action against Agila Specialties, Inc. in 2015 in the U.S. District Court for the District of New Jersey under the Hatch-Waxman framework.
What this type of case usually turns on. For this case type, the infringement allegations and defenses generally map to:
- Orange Book patent(s) listed for the reference listed drug (RLD)
- Whether Agila’s proposed product infringes each asserted claim
- Whether asserted claims are invalid (often for lack of novelty, obviousness, or anticipation) or unenforceable
- Whether the asserted patents are coextensive with the regulatory process or method claims
Why this matters commercially. The practical outcome typically determines the “at-risk” launch date for the proposed generic and whether AstraZeneca can secure injunctive relief or a binding settlement that delays entry.
Which patents were asserted in 1:15-cv-06039 and what do they cover?
Claim set identification is required to answer accurately. The case number alone does not specify:
- the drug(s) at issue
- the specific Orange Book patent numbers asserted
- whether the claims are product, formulation, method-of-use, or manufacturing/process
- the asserted independent claims and dependent claim tree
Without the asserted patent list and claim mapping, a reliable patent coverage and strength analysis cannot be produced.
How strong are AstraZeneca’s patents in this case: infringement and invalidity themes?
Typical AstraZeneca litigation posture (framework). In Hatch-Waxman actions involving complex oral/respiratory/oncology small molecules or drug-device analogs, AstraZeneca’s strength usually concentrates in:
- well-supported claim construction anchored to the specification
- lead compound/formulation ranges that map to accused compositions
- enforceable priority and nonobviousness arguments tied to comparative data
Typical generic invalidity posture (framework). Defendants such as Agila commonly argue:
- noninfringement based on compositional and parameter differences
- obviousness in view of prior art disclosures
- anticipation by earlier patents or publications
- lack of enablement or indefiniteness in edge cases
But case-specific strength cannot be quantified without record details. Patent strength grading requires:
- asserted claim language
- court’s claim construction rulings
- validity outcomes and any written reasons
No such record details are available from the case identifier alone.
What is the litigation timeline for 1:15-cv-06039 (filing to resolution)?
A complete litigation timeline requires docket facts such as:
- complaint filing date
- service and answer deadlines
- motions to dismiss and claim construction schedule
- summary judgment timing
- trial date(s) or stipulations
- settlement date or final judgment entry
The provided identifier does not include docket dates or outcome disposition text.
Did AstraZeneca win, settle, or lose in 1:15-cv-06039?
A correct answer depends on the final disposition:
- dismissal without prejudice
- dismissal with prejudice
- consent judgment
- summary judgment
- bench or jury verdict
- settlement with entry terms
The case identifier alone does not establish the outcome.
What are the Paragraph IV / Orange Book implications for Agila’s proposed generic under this case?
Paragraph IV typically implies. A Hatch-Waxman infringement suit usually follows a Paragraph IV certification challenging one or more Orange Book patents as:
What must be known to analyze.
- which Orange Book patents were certified under Paragraph IV
- whether the certification was “not infringed” or “invalid”
- which patents are later removed, amended, or found not infringed/invalid
Those facts are not ascertainable from the case number alone.
How does claim construction affect infringement risk in AstraZeneca v. Agila?
In Hatch-Waxman litigation, claim construction often drives outcomes:
- narrow interpretations can defeat infringement
- broad interpretations can preserve infringement but may increase invalidity risk
- means-plus-function and functional claim language can be outcome-determinative
A claim construction analysis requires the court’s Markman order and claim-by-claim construction. Those order details are not available here.
What generic launch risks exist for Agila based on this litigation?
Generic launch risk usually depends on:
- whether entry was enjoined pending final decision
- whether Agila received a launch approval “at risk” during litigation
- whether settlement imposed a date-certain entry or “carve-out” design changes
Without the disposition and any settlement terms, launch risk cannot be stated in a grounded way.
How might settlement terms typically allocate exclusivity and design-around freedom here?
In settlements, parties often agree to one or more of:
- a delayed launch date aligned with expiration of specific patents
- covenant-not-to-sue for certain claims/products
- market share or supply restrictions
- stipulations about design-around composition/process features
Settlement analysis requires actual agreement terms. The case identifier alone does not provide those terms.
Which FDA product and labeling (RLD, dosage form, route) is implicated by 1:15-cv-06039?
FDA product identification requires the Orange Book and complaint “parties and products” section:
- RLD name
- NDA/ANDA numbers
- strength and dosage form
- mechanism category and route
No product details are present in the prompt.
How does this case compare with other AstraZeneca vs. generic litigations on similar patents?
Benchmarking AstraZeneca’s posture across cases normally relies on:
- recurring asserted patents (same formulation or same method-of-use family)
- consistent claim construction positions across courts
- recurring defendants (often with similar generic formulation designs)
But a cross-case comparison cannot be executed without identifying:
- the drug family and patent family in 1:15-cv-06039
- the docket outcome and key rulings
Key Takeaways
- Case identification confirmed: AstraZeneca Pharmaceuticals LP v. Agila Specialties, Inc., District of New Jersey, case number 1:15-cv-06039.
- Patent and outcome details are not determinable from the provided identifier alone, which prevents an accurate infringement/invalidity analysis, timeline, settlement terms assessment, and generic launch-risk quantification.
- Actionable assessment requires docket-linked specifics (asserted Orange Book patents, claim constructions, and final disposition), which are not contained in the prompt.
FAQs
- What court rules and procedures govern Hatch-Waxman cases like 1:15-cv-06039 in the District of New Jersey?
- How do Paragraph IV certifications typically influence whether Agila can launch before patent expiration?
- What claim construction issues most often decide infringement in generic paragraph IV litigations?
- How do settlements in AstraZeneca-style Hatch-Waxman disputes usually structure delayed entry and design-around provisions?
- Where can Orange Book patent lists be used to map asserted patents to exclusivity and expiration dates in litigation?
References (APA)
- U.S. District Court for the District of New Jersey. AstraZeneca Pharmaceuticals LP v. Agila Specialties, Inc., No. 1:15-cv-06039.
